Implantable Port-a-Cath System Insertion in Patients with Metastatic Colon Cancer Receiving Bevacizumab-Based Chemotherapy

Abstract

Combination of bevacizumab with continuous 5- fluoracil (5-FU)-based regimens are considered to be the backbone of colorectal cancer (CRC) systemic therapy. Administration of these continuous intravenous regimens requires insertion of an indwelling central venous catheters and implantable port systems. Certain aspects of the toxicity profile of Bevacizumab could interfere with implantable port-a-cath insertion. The aim of present study was to evaluate the safety port-a-cath insertion shortly before or during bevacizumab treatment in patients with metastatic colon cancer.